ZYME

#1955
Zymeworks Inc.
27.7300 USD
+2.78%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
27.7300
27.7300
년간 변동
16.0034
28.4900
일일 변동
+2.78%
월간 변동
+19.68%
6달 변화
+56.31%
년간 변동율
+56.31%
이전 종가
26.9800
Open
27.7300
Bid
Ask
Low
27.7300
High
27.7300
양
220
Open full chart

Financials

Overview 성명 Statistics
Quarterly Annual
  • Market Capitalization 2.0451 B
  • Employee 264
  • Founded 2003
  • CEO Kenneth Galbraith
  • Website www.zymeworks.com
  • Headquarter Delaware, United States
  • FIGI BBG019XSYC89
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-24.38
Price to sales ratio
18.74

Zymeworks Inc

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

뉴스